175 related articles for article (PubMed ID: 2462074)
21. CI-922--a novel, potent antiallergic compound--II. Activity in animal models of allergy.
Adolphson RL; Finkel MP; Robichaud LJ
Int J Immunopharmacol; 1987; 9(1):51-60. PubMed ID: 2438239
[TBL] [Abstract][Full Text] [Related]
22. Antiallergic/antiasthmatic activity of oligopeptide related to IgE.
Singh R; Nath A; Gupta PP; Shulka M; Khare SK; Kundu B
Pharmacol Res; 1998 May; 37(5):353-6. PubMed ID: 9642030
[TBL] [Abstract][Full Text] [Related]
23. [Effect of KC-404 on allergic reactions types I-IV].
Nishino K; Hara S; Irikura T
Nihon Yakurigaku Zasshi; 1984 Apr; 83(4):291-9. PubMed ID: 6235160
[TBL] [Abstract][Full Text] [Related]
24. Effect of SN-408 (salmeterol hydroxynaphthoate) on passive cutaneous anaphylaxis and anaphylactic chemical mediator release in rats and guinea pigs.
Yamamura H; Kohno S; Ohata K
Arerugi; 1991 Jul; 40(7):669-79. PubMed ID: 1718245
[TBL] [Abstract][Full Text] [Related]
25. REV 2871 (CHBZ): a potent antiallergic agent with a novel mechanism of action. I. Activity profile as an inhibitor of mediator release.
Khandwala A; Coutts S; Pruss T; Jones H; Neiss E; Weinryb I
Biochem Pharmacol; 1987 Mar; 36(5):663-72. PubMed ID: 2435293
[TBL] [Abstract][Full Text] [Related]
26. Effects of antiallergic drugs on bronchial and cutaneous anaphylaxis in Lewis rats.
Misawa M; Takenouchi K; Kamishiro T; Yoshino Y; Yanaura S
J Pharmacobiodyn; 1988 Feb; 11(2):74-9. PubMed ID: 2454312
[TBL] [Abstract][Full Text] [Related]
27. [The pharmacological properties of a new anti-allergic agent, KP-136, in cutaneous models].
Kuriyama K; Hiyama Y; Ito K; Ichikawa K; Kitada S; Yoshinaka I
Nihon Yakurigaku Zasshi; 1987 Apr; 89(4):213-24. PubMed ID: 2440785
[TBL] [Abstract][Full Text] [Related]
28. Antiallergic/antiasthmatic effect of novel antiallergic hexapeptide-95/220 in various experimental models.
Singh R; Nath A; Gupta PP; Shukla M; Khare SK; Kundu B
Indian J Exp Biol; 2001 Sep; 39(9):871-7. PubMed ID: 11831367
[TBL] [Abstract][Full Text] [Related]
29. [Effect of predosing with Y-12,141 on its antiallergic activity. --Studies on anti-allergic agents(IV)-- (author's transl)].
Goto K; Terasawa M; Komori A; Maruyama Y
Nihon Yakurigaku Zasshi; 1981 Feb; 77(2):123-9. PubMed ID: 6786963
[TBL] [Abstract][Full Text] [Related]
30. A method for evaluating anti-allergic drugs by simultaneously induced passive cutaneous anaphylaxis and mediator cutaneous reactions.
Koda A; Miura T; Inagaki N; Sakamoto O; Arimura A; Nagai H; Mori H
Int Arch Allergy Appl Immunol; 1990; 92(3):209-16. PubMed ID: 1703513
[TBL] [Abstract][Full Text] [Related]
31. The effect of disodium cromoglycate and PGF2 alpha on acute cutaneous reactions of the guinea pig and rat.
Taylor WA
Int Arch Allergy Appl Immunol; 1973; 45(1):82-3. PubMed ID: 4199407
[No Abstract] [Full Text] [Related]
32. Antiallergic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidaz ole difumarate (KB-2413).
Fukuda T; Saito T; Tajima S; Shimohara K; Ito K
Arzneimittelforschung; 1984; 34(7):805-10. PubMed ID: 6208915
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo immunopharmacologic properties of a new antiallergic agent RHC 3414.
Khandwala A; Sonnino-Goldman P; Leibowitz M; Dally-Meade V; Donigi-Ruzza D
Arch Int Pharmacodyn Ther; 1984 Jan; 267(1):103-22. PubMed ID: 6202252
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of immediate hypersensitivity reactions in the rat by disodium cromoglycate and nitroindanedione.
Spicer BA; Ross JW; Smith H
Clin Exp Immunol; 1975 Sep; 21(3):419-29. PubMed ID: 812623
[TBL] [Abstract][Full Text] [Related]
35. Homologous passive cutaneous anaphylaxis (PCA) in mice and heterologous PCA induced in rats with mouse IgE.
Braga F; Mota I
Immunology; 1976 May; 30(5):655-69. PubMed ID: 179937
[TBL] [Abstract][Full Text] [Related]
36. BL-5255. I. Activity in animal models of immediate hypersensitivity reactions.
Siminoff P; Reed FC; Schurig JE
Int Arch Allergy Appl Immunol; 1982; 67(2):101-8. PubMed ID: 6799411
[TBL] [Abstract][Full Text] [Related]
37. Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
Makovec F; Peris W; Revel L; Giovanetti R; Redaelli D; Rovati LC
J Med Chem; 1992 Oct; 35(20):3633-40. PubMed ID: 1433173
[TBL] [Abstract][Full Text] [Related]
38. Antiallergic effects of 4-[2-oxo-3-(1H-tetrazol-5-yl)-2H-chromen-8-yloxy]-bu tyric acid.
Kuriyama K; Hiyama Y; Ito K
Jpn J Pharmacol; 1989 Jun; 50(2):111-8. PubMed ID: 2475659
[TBL] [Abstract][Full Text] [Related]
39. [Anti-allergic effects of tazanolast [butyl 3'-(1H-tetrazol-5-yl) oxanilate, WP-833] metabolites].
Hashimoto T; Edanami K; Naito A; Sano K; Fushimi H; Goto M
Nihon Yakurigaku Zasshi; 1990 Apr; 95(4):159-66. PubMed ID: 1695192
[TBL] [Abstract][Full Text] [Related]
40. Anti-allergic activities of the beta-adrenoceptor stimulant formoterol (BD 40A).
Tomioka K; Yamada T; Ida H
Arch Int Pharmacodyn Ther; 1981 Apr; 250(2):279-92. PubMed ID: 6168241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
